Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Feb 15, 2025; 17(2): 100546
Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.100546
Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.100546
Figure 1 Protein tyrosine phosphatase nonreceptor 2 gene mutations and gene expressions.
A: Tumors with protein tyrosine phosphatase nonreceptor 2 (PTPN2) mutations according to The Cancer Genome Atlas. Gastrointestinal (GI) cancers are marked with arrows; B: Distribution of PTPN2 gene expression in GI cancers and adjacent tissues according to GEPIA data. ESCA: Esophageal cancers; STAD: Stomach adenocarcinomas; COAD: Colon adenocarcinoma; LIHC: Liver hepatocellular carcinoma; Chol: Cholangiocarcinoma; PAAD: Pancreatic Adenocarcinoma.
Figure 2 Plots of gene copy number changes detected in gastrointestinal cancers among 10953 patients included in the The Cancer Genome Atlas PanCancer Atlas Studies investigating protein tyrosine phosphatase nonreceptor 2.
A: Esophageal cancer; B: Gastric cancer; C: Colorectal cancer; D: Liver hepatocellular carcinoma; E: Pancreatic adenocarcinoma.
- Citation: Gunizi OC, Elpek GO. Protein tyrosine phosphatase nonreceptor 2: A New biomarker for digestive tract cancers. World J Gastrointest Oncol 2025; 17(2): 100546
- URL: https://www.wjgnet.com/1948-5204/full/v17/i2/100546.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i2.100546